• news.cision.com/
  • Episurf/
  • Clinical data for Episealer® accepted for presentation at German scientific congress

Clinical data for Episealer® accepted for presentation at German scientific congress

Report this content

Episurf Medical (Nasdaq: EPIS B) today announces that the scientific abstract “Patient specific mini-metal implants. The future of cartilage repair for the right patient?” by Dr. med. J. Holz et al. has been accepted for presentation at the DKG (German Knee Society) annual congress in Hamburg, Germany, which will take place on November 22-23, 2019. The abstract focuses on clinical outcomes for patients in the “gap age”, 35-60 years old, that have undergone treatment of focal chondral defects using the knee implant Episealer®.

The abstract shows excellent early clinical results from the treatment of focal symptomatic cartilage lesions on the femoral condyles and the trochlea area of the knee with an individualised implant.

“We are very happy for the increasing interest in the Episealer® technology, but it is important to remember that this is because of the good clinical results that are achieved. The results are strong, the improvements are fast, it works for a wide age group, and from what we can see, the treatment seems to last for a long time. It is of course, very encouraging, to have these results presented at this important meeting” says Pål Ryfors, CEO, Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.